<DOC>
	<DOCNO>NCT00633841</DOCNO>
	<brief_summary>The purpose study assess tolerability safety repeat subcutaneous injection single dose AFFITOPE AD02 patient mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>Tolerability Safety Subcutaneous Administration AFFITOPE AD02 Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Alzheimer 's Disease ( AD ) devastate neurodegenerative disorder cure . Although etiology AD fully understood , recent research suggest Aβ central disease process . Consequently , approach capable remove Aβ brain , Aβ immunotherapy , expect possess disease-modifying potential . This view support evidence gather mouse model AD study involve AD patient . Based view active Aβ immunotherapy disease-modifying potential animal model AD patient , knowledge gather side-effects Aβ-based immunotherapy encounter human , design new generation AD vaccine . Rather use full length Aβ , choose use mimotopes N-terminal end Aβ antigenic component vaccine ( Mimotopes discover Affiris GmbH term AFFITOPES ) . Mimotopes peptides functionally mimic native antigenic epitope show sequence identity . Thus , different original antigen , mimotopes recognize antibody , vice versa , capable induce antibody cross-react original antigen . A major advantage offer mimotopes lack tolerance mechanism would prevent induction immune response ( case self peptides/proteins Aβ ) . To increase vaccine 's safety profile , length mimotope use limited preclude elicitation Aβ-specific T cell . Also , mimotope use design generate antibody direct exclusively Aβ ( i.e. , recognize parental APP ) . To provide helper epitope generation antibody response , mimotope couple carrier . The trial design patient-blinded , single-center , randomize , control , parallel group , phase I clinical study repeat every 4 week administration subcutaneous injection AFFITOPE AD02 alone adsorb aluminium hydroxide 24 patient mild moderate Alzheimer 's Disease . In total , patient receive 4 immunization . Patients randomize receive AFFITOPE AD02 alone adsorb alumimium hydroxide . Each treatment group consist 12 patient . For safety reason , inclusion patient do stepwise manner .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Main Diagnosis probable Alzheimer 's disease base NINCDS/ADRDA criterion . Alzheimer 's disease mild moderate degree ( MMSE 1626 ) Magnetic Resonance Imaging scan ( MRI ) brain consistent diagnosis AD . Written inform consent sign dated patient caregiver . Age 5080 year . Availability partner/caregiver Other Inclusion Criteria apply . Main Presence history allergy component vaccine . Contraindication MRI image . Participation another clinical trial . Prior and/or current treatment experimental immunotherapeutics include IVIG vaccine AD . Prior and/or current treatment immunosuppressive drug History and/or presence autoimmune disease . Other Exclusion Criteria apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>Morbus Alzheimer</keyword>
	<keyword>Alzheimer Vaccine</keyword>
	<keyword>Vaccine</keyword>
	<keyword>AD</keyword>
	<keyword>Aβ immunotherapy</keyword>
</DOC>